Literature DB >> 29020201

Novel Method Suggests Global Superiority of Short-Duration Antibiotics for Intra-abdominal Infections.

Arthur R Celestin1, Stephen R Odom1, Konstantia Angelidou2, Scott R Evans2, Raul Coimbra3, Christopher A Guidry4, Joseph Cuschieri5, Kaysie L Banton6, Patrick J O'Neill7, Reza Askari8, Nicholas Namias9, Therèse M Duane10, Jeffrey A Claridge11, E Patchen Dellinger5, Robert A Sawyer12, Charles H Cook1.   

Abstract

Desirability of outcome ranking and response adjusted for duration of antibiotic risk (DOOR/RADAR) are novel and innovative methods of evaluating data in antibiotic trials. We analyzed data from a noninferiority trial of short-course antimicrobial therapy for intra-abdominal infection (STOP-IT), and results suggest global superiority of short-duration therapy for intra-abdominal infections.
© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  antibiotic resistance; desirability of outcome ranking; duration of antibiotic therapy; intra-abdominal infection; surgical infection

Mesh：

Substances：

Year:  2017        PMID： 29020201      PMCID： PMC5850039          DOI： 10.1093/cid/cix569

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  9 in total

Review 1.  Coping with antibiotic resistance: the impending crisis.

Authors:  I M Gould
Journal:  Int J Antimicrob Agents       Date:  2010-11       Impact factor: 5.283

2.  Current issues in non-inferiority trials.

Authors:  Thomas R Fleming
Journal:  Stat Med       Date:  2008-02-10       Impact factor: 2.373

3.  Trial of short-course antimicrobial therapy for intraabdominal infection.

Authors:  Robert G Sawyer; Jeffrey A Claridge; Avery B Nathens; Ori D Rotstein; Therese M Duane; Heather L Evans; Charles H Cook; Patrick J O'Neill; John E Mazuski; Reza Askari; Mark A Wilson; Lena M Napolitano; Nicholas Namias; Preston R Miller; E Patchen Dellinger; Christopher M Watson; Raul Coimbra; Daniel L Dent; Stephen F Lowry; Christine S Cocanour; Michaela A West; Kaysie L Banton; William G Cheadle; Pamela A Lipsett; Christopher A Guidry; Kimberley Popovsky
Journal:  N Engl J Med       Date:  2015-05-21       Impact factor: 91.245

4.  Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR).

Authors:  Scott R Evans; Daniel Rubin; Dean Follmann; Gene Pennello; W Charles Huskins; John H Powers; David Schoenfeld; Christy Chuang-Stein; Sara E Cosgrove; Vance G Fowler; Ebbing Lautenbach; Henry F Chambers
Journal:  Clin Infect Dis       Date:  2015-06-25       Impact factor: 9.079

5.  Using Outcomes to Analyze Patients Rather than Patients to Analyze Outcomes: A Step toward Pragmatism in Benefit:risk Evaluation.

Authors:  Scott R Evans; Dean Follmann
Journal:  Stat Biopharm Res       Date:  2016-12-06       Impact factor: 1.452

Review 6.  The clinical consequences of antimicrobial resistance.

Authors:  Louis B Rice
Journal:  Curr Opin Microbiol       Date:  2009-08-27       Impact factor: 7.934

7.  Risk factors for Clostridium difficile infection.

Authors:  G E Bignardi
Journal:  J Hosp Infect       Date:  1998-09       Impact factor: 3.926

8.  Another setting for stewardship: high rate of unnecessary antimicrobial use in a veterans affairs long-term care facility.

Authors:  Emily P Peron; Amy A Hirsch; Lucy A Jury; Robin L P Jump; Curtis J Donskey
Journal:  J Am Geriatr Soc       Date:  2013-02       Impact factor: 5.562

Review 9.  Antibiotic stewardship in the intensive care unit.

Authors:  Charles-Edouard Luyt; Nicolas Bréchot; Jean-Louis Trouillet; Jean Chastre
Journal:  Crit Care       Date:  2014-08-13       Impact factor: 9.097
  9 in total
  5 in total

1.  Desirability of outcome ranking (DOOR) for comparing diagnostic tools and early therapeutic choices in patients with suspected candidemia.

Authors:  Daniele Roberto Giacobbe; Alessio Signori; Mario Tumbarello; Riccardo Ungaro; Giovanni Sarteschi; Elisa Furfaro; Malgorzata Mikulska; Maurizio Sanguinetti; Brunella Posteraro; Angela Raffaella Losito; Gennaro De Pascale; Valerio Del Bono; Claudio Viscoli
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-11-30       Impact factor: 3.267

2.  Elaboration of Consensus Clinical Endpoints to Evaluate Antimicrobial Treatment Efficacy in Future Hospital-acquired/Ventilator-associated Bacterial Pneumonia Clinical Trials.

Authors:  Emmanuel Weiss; Jean-Ralph Zahar; Jeff Alder; Karim Asehnoune; Matteo Bassetti; Marc J M Bonten; Jean Chastre; Jan De Waele; George Dimopoulos; Philippe Eggimann; Marc Engelhardt; Santiago Ewig; Marin Kollef; Jeffrey Lipman; Carlos Luna; Ignacio Martin-Loeches; Leonardo Pagani; Lucy B Palmer; Laurent Papazian; Garyphallia Poulakou; Philippe Prokocimer; Jordi Rello; John H Rex; Andrew F Shorr; George H Talbot; Visanu Thamlikitkul; Antoni Torres; Richard G Wunderink; Jean-François Timsit
Journal:  Clin Infect Dis       Date:  2019-11-13       Impact factor: 20.999

3.  A randomised placebo-controlled double-blind multicentre trial comparing antibiotic therapy with placebo in the treatment of uncomplicated acute appendicitis: APPAC III trial study protocol.

Authors:  Suvi Sippola; Juha Grönroos; Ville Sallinen; Tero Rautio; Pia Nordström; Tuomo Rantanen; Saija Hurme; Ari Leppäniemi; Sanna Meriläinen; Johanna Laukkarinen; Heini Savolainen; Johanna Virtanen; Paulina Salminen
Journal:  BMJ Open       Date:  2018-11-03       Impact factor: 2.692

4.  Microbiological and host-derived biomarker evaluation following non-surgical periodontal therapy with short-term administration of systemic antimicrobials: secondary outcomes of an RCT.

Authors:  Raluca Cosgarea; S Eick; S Jepsen; N B Arweiler; R Juncar; R Tristiu; G E Salvi; C Heumann; A Sculean
Journal:  Sci Rep       Date:  2020-10-01       Impact factor: 4.379

5.  Serial analysis of blood biomarker concentrations in dogs with pneumonia, septic peritonitis, and pyometra.

Authors:  Robert Goggs; Sarah N Robbins; Denise M LaLonde-Paul; Julie M Menard
Journal:  J Vet Intern Med       Date:  2022-02-01       Impact factor: 3.333
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.